Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
GSK-4418959 (IDE275): A Comprehensive Analysis of a Novel, Reversible WRN Inhibitor Poised to Redefine Treatment for MSI-High Solid Tumors
Section 1: Executive Summary
GSK-4418959, also identified as IDE275, is an orally bioavailable, small-molecule inhibitor emerging from a strategic collaboration between GlaxoSmithKline (GSK) and IDEAYA Biosciences. This investigational agent is positioned as a potential first-in-class and best-in-class therapeutic targeting Werner syndrome helicase (WRN), a pivotal enzyme in the DNA damage response (DDR) pathway. The development of GSK-4418959 embodies a precision oncology strategy founded on the principle of synthetic lethality, aiming to exploit a specific genetic vulnerability present in a well-defined subset of solid tumors.
The drug's therapeutic focus is on patients with solid tumors characterized by high microsatellite instability (MSI-H) or deficient DNA mismatch repair (dMMR). In these cancer cells, the loss of the primary DNA repair function of the MMR system creates a critical dependency on the WRN helicase to resolve complex DNA structures and maintain genomic integrity during replication. By inhibiting the helicase activity of WRN, GSK-4418959 is designed to induce an overwhelming accumulation of DNA damage, leading to catastrophic replication stress and the selective death of cancer cells, while sparing healthy, microsatellite-stable (MSS) cells.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/11/29 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.